Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Refractory Solid Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00193570
What this trial is testing

Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

Who this might be right for
Cancer
SCRI Development Innovations, LLC 20
Early research (Phase 1)Study completedNCT00275080
What this trial is testing

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+48 more
National Cancer Institute (NCI) 80
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439357
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 4
Early research (Phase 1)Study completedNCT03941262
What this trial is testing

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Who this might be right for
Refractory CancerMetastatic CancerRecurrent Cancer+4 more
NKGen Biotech, Inc. 27
Early research (Phase 1)Study completedNCT00014261
What this trial is testing

Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Dartmouth-Hitchcock Medical Center
Early research (Phase 1)Study completedNCT00004059
What this trial is testing

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT00968981
What this trial is testing

Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 67
Not applicableNo Longer AvailableNCT05511350
What this trial is testing

Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001

Who this might be right for
Solid Tumor Metastatic Cancer Advanced Cancer
I-Mab Biopharma US Limited
Testing effectiveness (Phase 2)Active Not RecruitingNCT03213652
What this trial is testing

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmMalignant Solid NeoplasmRecurrent Ependymoma+30 more
National Cancer Institute (NCI) 13
Testing effectiveness (Phase 2)Study completedNCT03220035
What this trial is testing

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more
National Cancer Institute (NCI) 4
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Testing effectiveness (Phase 2)UnknownNCT02839954
What this trial is testing

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Who this might be right for
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic Carcinoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Study completedNCT00567931
What this trial is testing

1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)Looking for participantsNCT06320405
What this trial is testing

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm+1 more
OHSU Knight Cancer Institute 38
Early research (Phase 1)Looking for participantsNCT06132503
What this trial is testing

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Who this might be right for
Relapsed or Refractory LymphomasAdvanced Solid Tumor
Lantern Pharma Inc. 110
Early research (Phase 1)Looking for participantsNCT07620041
What this trial is testing

Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Who this might be right for
Refractory or Relapsed Solid Tumors
Qilu Pharmaceutical Co., Ltd. 48
Early research (Phase 1)Looking for participantsNCT06880549
What this trial is testing

MRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

Who this might be right for
Advanced Solid Tumors
ModernaTX, Inc. 42
Early research (Phase 1)WithdrawnNCT05231733
What this trial is testing

Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors

Who this might be right for
Solid Tumors
SparX Biotech(Jiangsu) Co., Ltd.
Early research (Phase 1)Looking for participantsNCT07492628
What this trial is testing

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech 42
Next Page